| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Drug Resistance, Viral | 22 | 2021 | 1083 | 2.23 | Why? |
| HIV-1 | 30 | 2020 | 3365 | 2.04 | Why? |
| HIV Integrase Inhibitors | 5 | 2019 | 173 | 1.72 | Why? |
| HIV Integrase | 5 | 2018 | 67 | 1.53 | Why? |
| HIV Infections | 36 | 2020 | 11620 | 1.13 | Why? |
| Anti-HIV Agents | 19 | 2020 | 2209 | 1.12 | Why? |
| HIV Protease | 8 | 2019 | 86 | 1.01 | Why? |
| HIV Protease Inhibitors | 6 | 2019 | 434 | 0.83 | Why? |
| Viral Load | 27 | 2021 | 15850 | 0.72 | Why? |
| HIV-2 | 6 | 2019 | 92 | 0.64 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 4 | 2019 | 95 | 0.56 | Why? |
| Mutation | 16 | 2021 | 12376 | 0.50 | Why? |
| Drug Resistance, Multiple, Viral | 3 | 2019 | 37 | 0.47 | Why? |
| Mutation, Missense | 1 | 2018 | 863 | 0.47 | Why? |
| Emtricitabine | 5 | 2018 | 202 | 0.45 | Why? |
| Genotype | 11 | 2020 | 4697 | 0.44 | Why? |
| Multiplex Polymerase Chain Reaction | 7 | 2021 | 1439 | 0.44 | Why? |
| Darunavir | 4 | 2018 | 477 | 0.43 | Why? |
| Immunoassay | 3 | 2021 | 4485 | 0.37 | Why? |
| Rilpivirine | 2 | 2019 | 65 | 0.37 | Why? |
| Atazanavir Sulfate | 3 | 2018 | 213 | 0.33 | Why? |
| Tenofovir | 4 | 2018 | 449 | 0.33 | Why? |
| France | 17 | 2021 | 12074 | 0.30 | Why? |
| Furans | 3 | 2020 | 156 | 0.29 | Why? |
| CD4 Lymphocyte Count | 9 | 2019 | 1517 | 0.27 | Why? |
| HIV Reverse Transcriptase | 3 | 2018 | 104 | 0.27 | Why? |
| beta-Cyclodextrins | 2 | 2020 | 87 | 0.26 | Why? |
| Treatment Failure | 5 | 2020 | 2106 | 0.25 | Why? |
| HIV | 3 | 2019 | 1116 | 0.24 | Why? |
| Raltegravir Potassium | 3 | 2018 | 132 | 0.24 | Why? |
| Reverse Transcriptase Inhibitors | 3 | 2018 | 309 | 0.24 | Why? |
| Antiretroviral Therapy, Highly Active | 5 | 2018 | 952 | 0.23 | Why? |
| Triazines | 2 | 2020 | 246 | 0.23 | Why? |
| HIV Envelope Protein gp41 | 2 | 2019 | 153 | 0.22 | Why? |
| Piperazines | 3 | 2018 | 445 | 0.22 | Why? |
| Pyrroles | 2 | 2020 | 292 | 0.21 | Why? |
| Herpesvirus 8, Human | 2 | 2018 | 97 | 0.21 | Why? |
| High-Throughput Nucleotide Sequencing | 8 | 2019 | 3633 | 0.21 | Why? |
| Sarcoma, Kaposi | 2 | 2018 | 97 | 0.21 | Why? |
| Papillomavirus Infections | 2 | 2019 | 861 | 0.20 | Why? |
| Ritonavir | 5 | 2020 | 4212 | 0.20 | Why? |
| Lupus Erythematosus, Cutaneous | 1 | 2020 | 104 | 0.19 | Why? |
| APOBEC-3G Deaminase | 1 | 2018 | 33 | 0.19 | Why? |
| Gene Frequency | 3 | 2018 | 1210 | 0.19 | Why? |
| Emtricitabine, Rilpivirine, Tenofovir Drug Combination | 1 | 2018 | 3 | 0.19 | Why? |
| Molecular Diagnostic Techniques | 3 | 2020 | 4239 | 0.19 | Why? |
| Quinolones | 2 | 2017 | 167 | 0.19 | Why? |
| Mucosal-Associated Invariant T Cells | 1 | 2021 | 170 | 0.19 | Why? |
| Interleukin-18 | 1 | 2021 | 328 | 0.19 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 39 | 0.18 | Why? |
| Organophosphates | 1 | 2018 | 66 | 0.18 | Why? |
| Heterocyclic Compounds, 3-Ring | 2 | 2018 | 275 | 0.18 | Why? |
| Hyaluronan Receptors | 1 | 2018 | 61 | 0.18 | Why? |
| Clinical Laboratory Techniques | 8 | 2021 | 23402 | 0.18 | Why? |
| HIV Long Terminal Repeat | 1 | 2017 | 16 | 0.18 | Why? |
| Immunomagnetic Separation | 1 | 2018 | 55 | 0.18 | Why? |
| Alphapapillomavirus | 1 | 2018 | 107 | 0.17 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 13720 | 0.16 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.16 | Why? |
| Itraconazole | 1 | 2018 | 135 | 0.16 | Why? |
| Polymorphism, Genetic | 3 | 2019 | 1074 | 0.16 | Why? |
| Codon | 1 | 2018 | 287 | 0.16 | Why? |
| Sensitivity and Specificity | 10 | 2021 | 22971 | 0.16 | Why? |
| Herpesviridae Infections | 1 | 2018 | 172 | 0.16 | Why? |
| Superinfection | 1 | 2021 | 459 | 0.16 | Why? |
| Cobicistat | 1 | 2017 | 172 | 0.16 | Why? |
| Viremia | 3 | 2019 | 1020 | 0.16 | Why? |
| Reagent Kits, Diagnostic | 3 | 2021 | 2149 | 0.15 | Why? |
| Capsid | 1 | 2017 | 197 | 0.15 | Why? |
| Cerebrospinal Fluid | 1 | 2017 | 234 | 0.15 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.15 | Why? |
| DNA, Viral | 4 | 2019 | 2521 | 0.15 | Why? |
| Virus Cultivation | 1 | 2018 | 579 | 0.14 | Why? |
| Drug Interactions | 2 | 2020 | 1653 | 0.14 | Why? |
| Male | 50 | 2021 | 367725 | 0.13 | Why? |
| Carbamates | 1 | 2018 | 485 | 0.13 | Why? |
| Humans | 73 | 2021 | 930598 | 0.13 | Why? |
| Amino Acid Substitution | 2 | 2018 | 1706 | 0.13 | Why? |
| Adult | 39 | 2021 | 244371 | 0.13 | Why? |
| Respiratory Tract Infections | 3 | 2021 | 6817 | 0.13 | Why? |
| Hospital Administration | 1 | 2020 | 650 | 0.13 | Why? |
| Middle Aged | 39 | 2021 | 270681 | 0.13 | Why? |
| Homosexuality, Male | 2 | 2019 | 1158 | 0.12 | Why? |
| Organophosphonates | 1 | 2013 | 85 | 0.12 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2019 | 533 | 0.12 | Why? |
| Interferon-alpha | 1 | 2021 | 1442 | 0.12 | Why? |
| Deoxycytidine | 1 | 2013 | 116 | 0.12 | Why? |
| Prevalence | 9 | 2021 | 25773 | 0.12 | Why? |
| Recombination, Genetic | 1 | 2019 | 1265 | 0.12 | Why? |
| Lung Transplantation | 2 | 2020 | 1554 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.12 | Why? |
| Paris | 3 | 2021 | 1287 | 0.12 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.11 | Why? |
| Female | 43 | 2021 | 380317 | 0.11 | Why? |
| Serologic Tests | 3 | 2020 | 4359 | 0.11 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.11 | Why? |
| Virus Diseases | 2 | 2021 | 3779 | 0.11 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.11 | Why? |
| Sexually Transmitted Diseases | 1 | 2019 | 694 | 0.11 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2020 | 1138 | 0.11 | Why? |
| Structure-Activity Relationship | 1 | 2018 | 2219 | 0.11 | Why? |
| Point-of-Care Testing | 2 | 2021 | 2782 | 0.11 | Why? |
| Sulfonamides | 2 | 2018 | 1294 | 0.11 | Why? |
| Genetic Variation | 3 | 2020 | 3919 | 0.11 | Why? |
| Plasma | 2 | 2018 | 1809 | 0.10 | Why? |
| Adenine | 1 | 2013 | 463 | 0.10 | Why? |
| Phylogeny | 5 | 2020 | 13341 | 0.10 | Why? |
| Hepatitis B virus | 1 | 2017 | 882 | 0.10 | Why? |
| Pyrrolidinones | 1 | 2009 | 66 | 0.10 | Why? |
| Homeless Persons | 1 | 2021 | 1171 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.10 | Why? |
| Chilblains | 1 | 2020 | 1156 | 0.10 | Why? |
| Oligopeptides | 1 | 2013 | 576 | 0.09 | Why? |
| Pneumonia, Ventilator-Associated | 1 | 2017 | 861 | 0.09 | Why? |
| Immunoglobulin M | 3 | 2021 | 9091 | 0.09 | Why? |
| Drug Therapy, Combination | 5 | 2020 | 7268 | 0.09 | Why? |
| Macrophages | 1 | 2021 | 2784 | 0.09 | Why? |
| Monocytes | 1 | 2021 | 2978 | 0.09 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.09 | Why? |
| Sequence Analysis, RNA | 1 | 2017 | 2290 | 0.09 | Why? |
| Pneumonia, Viral | 13 | 2020 | 243684 | 0.09 | Why? |
| Betacoronavirus | 12 | 2020 | 204454 | 0.09 | Why? |
| Viruses | 2 | 2021 | 2238 | 0.09 | Why? |
| Seasons | 2 | 2017 | 4071 | 0.09 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.08 | Why? |
| Models, Molecular | 2 | 2019 | 7616 | 0.08 | Why? |
| Lamivudine | 2 | 2018 | 210 | 0.08 | Why? |
| Tablets | 2 | 2018 | 219 | 0.08 | Why? |
| Enzyme Inhibitors | 1 | 2018 | 1881 | 0.08 | Why? |
| Pyridines | 1 | 2013 | 680 | 0.08 | Why? |
| Cohort Studies | 9 | 2021 | 36005 | 0.08 | Why? |
| Intensive Care Units | 5 | 2020 | 29594 | 0.08 | Why? |
| HIV Seropositivity | 2 | 2019 | 320 | 0.08 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.08 | Why? |
| Renal Dialysis | 2 | 2020 | 4358 | 0.08 | Why? |
| Adenosine | 2 | 2020 | 509 | 0.08 | Why? |
| Coronavirus Infections | 12 | 2020 | 253789 | 0.08 | Why? |
| Hospitals | 3 | 2021 | 11793 | 0.08 | Why? |
| Oxazines | 2 | 2018 | 279 | 0.08 | Why? |
| Adenosine Monophosphate | 2 | 2020 | 5652 | 0.08 | Why? |
| Alanine | 2 | 2020 | 5687 | 0.08 | Why? |
| Coinfection | 3 | 2021 | 6820 | 0.08 | Why? |
| Aged | 20 | 2021 | 215776 | 0.08 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.07 | Why? |
| Sequence Analysis, DNA | 3 | 2020 | 2830 | 0.07 | Why? |
| Genotyping Techniques | 2 | 2018 | 360 | 0.07 | Why? |
| RNA, Viral | 11 | 2021 | 32276 | 0.07 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.07 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 11367 | 0.07 | Why? |
| Immunocompromised Host | 1 | 2021 | 5150 | 0.07 | Why? |
| Virus Shedding | 1 | 2021 | 5834 | 0.07 | Why? |
| Protein Conformation | 3 | 2019 | 4386 | 0.06 | Why? |
| Amino Acid Sequence | 3 | 2019 | 6049 | 0.06 | Why? |
| Aged, 80 and over | 10 | 2021 | 88759 | 0.06 | Why? |
| Sequence Alignment | 2 | 2019 | 2109 | 0.06 | Why? |
| Virulence | 2 | 2020 | 2172 | 0.06 | Why? |
| Limit of Detection | 2 | 2020 | 2698 | 0.06 | Why? |
| Pyridones | 2 | 2018 | 738 | 0.06 | Why? |
| Administration, Oral | 2 | 2020 | 2340 | 0.06 | Why? |
| Pharmaceutical Solutions | 1 | 2020 | 24 | 0.06 | Why? |
| Young Adult | 10 | 2021 | 93724 | 0.05 | Why? |
| Seroepidemiologic Studies | 3 | 2021 | 10017 | 0.05 | Why? |
| Nasopharynx | 4 | 2021 | 10224 | 0.05 | Why? |
| Neuroglia | 1 | 2020 | 130 | 0.05 | Why? |
| Models, Biological | 1 | 2018 | 4907 | 0.05 | Why? |
| Drug Monitoring | 2 | 2019 | 1408 | 0.05 | Why? |
| Models, Theoretical | 1 | 2019 | 6659 | 0.05 | Why? |
| Retrospective Studies | 10 | 2021 | 105322 | 0.05 | Why? |
| Interleukin-15 | 1 | 2021 | 169 | 0.05 | Why? |
| Guinea-Bissau | 1 | 2019 | 22 | 0.05 | Why? |
| Togo | 1 | 2019 | 95 | 0.05 | Why? |
| Immunoprecipitation | 1 | 2020 | 300 | 0.05 | Why? |
| Pliability | 1 | 2019 | 36 | 0.05 | Why? |
| Sexual and Gender Minorities | 2 | 2020 | 1019 | 0.05 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2021 | 9335 | 0.05 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.05 | Why? |
| Integrase Inhibitors | 1 | 2018 | 27 | 0.05 | Why? |
| Apolipoproteins B | 1 | 2018 | 47 | 0.05 | Why? |
| Lymphoma, Primary Effusion | 1 | 2018 | 11 | 0.05 | Why? |
| Blood | 1 | 2020 | 274 | 0.05 | Why? |
| Emergency Service, Hospital | 2 | 2020 | 14232 | 0.05 | Why? |
| Castleman Disease | 1 | 2018 | 28 | 0.05 | Why? |
| Cytochrome P-450 CYP3A Inhibitors | 1 | 2020 | 256 | 0.05 | Why? |
| Microbial Sensitivity Tests | 2 | 2018 | 2886 | 0.05 | Why? |
| Luciferases | 1 | 2020 | 378 | 0.05 | Why? |
| Dideoxynucleosides | 1 | 2018 | 92 | 0.05 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Metabolic Clearance Rate | 1 | 2018 | 110 | 0.04 | Why? |
| Pilot Projects | 2 | 2021 | 5182 | 0.04 | Why? |
| Human papillomavirus 16 | 1 | 2018 | 95 | 0.04 | Why? |
| Pandemics | 14 | 2021 | 389249 | 0.04 | Why? |
| Histoplasmosis | 1 | 2018 | 83 | 0.04 | Why? |
| Sequence Analysis, Protein | 1 | 2018 | 309 | 0.04 | Why? |
| Protein Binding | 3 | 2019 | 11430 | 0.04 | Why? |
| Cervix Uteri | 1 | 2018 | 146 | 0.04 | Why? |
| Half-Life | 1 | 2018 | 298 | 0.04 | Why? |
| Urine | 1 | 2020 | 469 | 0.04 | Why? |
| Bronchoalveolar Lavage | 1 | 2021 | 603 | 0.04 | Why? |
| Prospective Studies | 5 | 2021 | 43301 | 0.04 | Why? |
| Picornaviridae | 1 | 2017 | 123 | 0.04 | Why? |
| Nonlinear Dynamics | 1 | 2018 | 177 | 0.04 | Why? |
| Maintenance Chemotherapy | 1 | 2017 | 133 | 0.04 | Why? |
| Risk Factors | 6 | 2021 | 71621 | 0.04 | Why? |
| Neutralization Tests | 2 | 2020 | 6698 | 0.04 | Why? |
| Drug Dosage Calculations | 1 | 2018 | 243 | 0.04 | Why? |
| Hydrogen Bonding | 1 | 2019 | 599 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Conserved Sequence | 1 | 2019 | 751 | 0.04 | Why? |
| Genome, Viral | 1 | 2018 | 13157 | 0.04 | Why? |
| HIV Envelope Protein gp120 | 1 | 2018 | 267 | 0.04 | Why? |
| Heterosexuality | 1 | 2017 | 148 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Binding Sites | 2 | 2019 | 6201 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Immunophenotyping | 1 | 2021 | 1290 | 0.04 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Phylogeography | 1 | 2019 | 824 | 0.04 | Why? |
| Anal Canal | 1 | 2018 | 367 | 0.04 | Why? |
| Papillomaviridae | 1 | 2019 | 404 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.04 | Why? |
| European Union | 1 | 2019 | 565 | 0.04 | Why? |
| Mental Disorders | 1 | 2018 | 6742 | 0.04 | Why? |
| Protein Subunits | 1 | 2018 | 755 | 0.04 | Why? |
| Interleukin-8 | 1 | 2021 | 964 | 0.04 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.04 | Why? |
| Drug Substitution | 1 | 2018 | 385 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.03 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2020 | 1444 | 0.03 | Why? |
| Inhibitory Concentration 50 | 1 | 2017 | 907 | 0.03 | Why? |
| Chromatography, Liquid | 1 | 2018 | 640 | 0.03 | Why? |
| Polymerase Chain Reaction | 2 | 2021 | 6740 | 0.03 | Why? |
| Protein Structure, Tertiary | 1 | 2018 | 1565 | 0.03 | Why? |
| Transplant Recipients | 2 | 2020 | 4982 | 0.03 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.03 | Why? |
| Interleukin-10 | 1 | 2021 | 1409 | 0.03 | Why? |
| Ligands | 1 | 2019 | 1300 | 0.03 | Why? |
| Computer Simulation | 2 | 2019 | 4982 | 0.03 | Why? |
| Treatment Outcome | 2 | 2018 | 51732 | 0.03 | Why? |
| Respiratory Syncytial Viruses | 1 | 2017 | 612 | 0.03 | Why? |
| Adolescent | 5 | 2021 | 86841 | 0.03 | Why? |
| Tandem Mass Spectrometry | 1 | 2018 | 1031 | 0.03 | Why? |
| Algorithms | 2 | 2019 | 7346 | 0.03 | Why? |
| Flow Cytometry | 1 | 2020 | 2393 | 0.03 | Why? |
| Genes, Viral | 1 | 2017 | 1428 | 0.03 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.03 | Why? |
| Adenoviridae | 1 | 2017 | 1151 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Virus Attachment | 1 | 2018 | 1259 | 0.03 | Why? |
| Cluster Analysis | 1 | 2019 | 3001 | 0.03 | Why? |
| Disease Management | 2 | 2019 | 6841 | 0.03 | Why? |
| Viral Proteins | 2 | 2020 | 7370 | 0.03 | Why? |
| Area Under Curve | 1 | 2018 | 2564 | 0.03 | Why? |
| Single-Cell Analysis | 1 | 2021 | 2450 | 0.03 | Why? |
| Crystallography, X-Ray | 1 | 2018 | 2689 | 0.03 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.03 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.02 | Why? |
| Feasibility Studies | 1 | 2019 | 3467 | 0.02 | Why? |
| Switzerland | 1 | 2017 | 2738 | 0.02 | Why? |
| Pyridazines | 1 | 2009 | 86 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2021 | 48226 | 0.02 | Why? |
| Orthomyxoviridae | 1 | 2017 | 1168 | 0.02 | Why? |
| Drug Combinations | 1 | 2018 | 3852 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2019 | 3239 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Respiratory System | 1 | 2020 | 3213 | 0.02 | Why? |
| Patient Isolation | 1 | 2021 | 3182 | 0.02 | Why? |
| Respiratory Syncytial Virus Infections | 1 | 2017 | 1234 | 0.02 | Why? |
| Interferon Type I | 1 | 2020 | 2789 | 0.02 | Why? |
| Comorbidity | 2 | 2021 | 34796 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Feces | 1 | 2020 | 4235 | 0.02 | Why? |
| Infant | 2 | 2021 | 30274 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2019 | 4002 | 0.02 | Why? |
| Bacteria | 1 | 2017 | 1897 | 0.02 | Why? |
| Evolution, Molecular | 1 | 2020 | 3691 | 0.02 | Why? |
| Software | 1 | 2018 | 2501 | 0.02 | Why? |
| Drug Administration Schedule | 1 | 2013 | 2324 | 0.02 | Why? |
| Public Health Surveillance | 1 | 2019 | 3129 | 0.02 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.02 | Why? |
| Child, Preschool | 2 | 2021 | 36283 | 0.02 | Why? |
| Nitriles | 1 | 2009 | 1053 | 0.02 | Why? |
| Chronic Disease | 1 | 2019 | 5139 | 0.02 | Why? |
| Vero Cells | 1 | 2021 | 14117 | 0.02 | Why? |
| RNA, Messenger | 1 | 2018 | 5131 | 0.02 | Why? |
| Body Mass Index | 1 | 2017 | 4306 | 0.02 | Why? |
| Drug Discovery | 1 | 2018 | 3092 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2018 | 4545 | 0.02 | Why? |
| Medication Adherence | 1 | 2013 | 1270 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2018 | 6902 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Europe | 1 | 2019 | 12702 | 0.01 | Why? |
| Population Surveillance | 1 | 2019 | 4967 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Pyrimidines | 1 | 2009 | 1557 | 0.01 | Why? |
| Child | 3 | 2021 | 70012 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 1998 | 5164 | 0.01 | Why? |
| Travel | 1 | 2020 | 7220 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2019 | 17020 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2019 | 43792 | 0.01 | Why? |
| Tumor Cells, Cultured | 1 | 1998 | 254 | 0.01 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2021 | 9706 | 0.01 | Why? |
| Prognosis | 1 | 2021 | 32490 | 0.01 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.01 | Why? |
| Age Factors | 1 | 2017 | 21039 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Hospital Mortality | 1 | 2017 | 22087 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2019 | 53120 | 0.01 | Why? |
| Animals | 1 | 2021 | 78931 | 0.01 | Why? |
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 37182 | 0.01 | Why? |